1 414-918-9890

Sen Zhuang, MD, PhD


Sen Zhuang MD, PhD is currently Vice President, Head of Hematology Development at Janssen Oncology R&D. He oversees the global clinical development of late-stage hematologic assets including ibrutinib, daratumumab, cilta-cel (BCMA-CAR-T), teclistamab, talquetamab and other emerging late-stage hematologic compounds.  These programs lead to over 25 global approvals and received 8 US FDA breakthrough designations and 3 EMA PRIME designations. Over half million patients around the world have been treated with these therapies. Sen is a graduate from Sun Yat-Sen University of Medical Sciences in Guangzhou, China. He earned a PhD degree in Molecular and Cellular Pharmacology for University of Miami School of Medicine in Miami, Florida. He received his residency training in Internal Medicine from Albert Einstein Medical College Long Island campus (Long Island Jewish Medical Center). He completed his Medical Oncology and Hematology fellowship in National Cancer Institute (NCI) and National Heart Lung and Blood Institute (NHLBI) in Bethesda, Maryland. He is board certified in Internal Medicine, Medical Oncology, and Hematology.

Cookie Notice

This website uses cookies to deliver to you the best experience possible on the CAHON website. By continuing to use this site, you are providing to us your consent to ensure you receive such an experience. View our privacy policy to learn more.